UBS Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-45,436
| Closed | -$72.2K | – | 10449 |
|
|
2024
Q1 | $72.2K | Sell |
45,436
-1,368
| -3% | -$2.03K | ﹤0.01% | 6352 |
|
|
2023
Q4 | $40.2K | Buy |
46,804
+24,624
| +111% | +$21.6K | ﹤0.01% | 6669 |
|
|
2023
Q3 | $23.7K | Buy |
+22,180
| New | +$45.9K | ﹤0.01% | 6714 |
|
|
2023
Q2 | – | Sell |
-2,896
| Closed | -$11.8K | – | 9996 |
|
|
2023
Q1 | $11.8K | Sell |
2,896
-1,835
| -39% | -$8.48K | ﹤0.01% | 7475 |
|
|
2022
Q4 | $23.8K | Buy |
+4,731
| New | +$29.7K | ﹤0.01% | 7474 |
|
|
2022
Q1 | – | Sell |
-2,673
| Closed | -$47K | – | 11142 |
|
|
2021
Q4 | $47K | Buy |
2,673
+1,866
| +231% | +$35.8K | ﹤0.01% | 6973 |
|
|
2021
Q3 | $17K | Sell |
807
-4,140
| -84% | -$91.1K | ﹤0.01% | 7365 |
|
|
2021
Q2 | $98K | Sell |
4,947
-37,253
| -88% | -$872K | ﹤0.01% | 5897 |
|
|
2021
Q1 | $1.23M | Buy |
42,200
+23,900
| +131% | +$669K | ﹤0.01% | 4052 |
|
|
2020
Q4 | $554K | Buy |
18,300
+6,000
| +49% | +$131K | ﹤0.01% | 4523 |
|
|
2020
Q3 | $196K | Buy |
12,300
+2,711
| +28% | +$49.5K | ﹤0.01% | 4807 |
|
|
2020
Q2 | $189K | Sell |
9,589
-945
| -9% | -$18.1K | ﹤0.01% | 4841 |
|
|
2020
Q1 | $130K | Sell |
10,534
-16,125
| -60% | -$263K | ﹤0.01% | 5058 |
|
|
2019
Q4 | $492K | Buy |
26,659
+17,542
| +192% | +$256K | ﹤0.01% | 4850 |
|
|
2019
Q3 | $127K | Buy |
9,117
+7,904
| +652% | +$119K | ﹤0.01% | 5611 |
|
|
2019
Q2 | $18K | Buy |
+1,213
| New | +$17.8K | ﹤0.01% | 6698 |
|
UBS Group's NGM Position: Q2 2024 in Review
UBS Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 45,436 shares — an estimated $72.2K sold.
UBS Group first reported a position in NGM in Q2 2019 and held it in 16 quarters. The position peaked at $1.23M in Q1 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- UBS Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 45,436 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $72.2K.
- UBS Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- UBS Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.23M in Q1 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.